Key facts
- This page summarizes Curnutte John T.'s Form 4 filing for Orchard Therapeutics plc.
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Jan 2024, 17:16.
Curnutte John T. - 24 Jan 2024 Form 4 Insider Report for Orchard Therapeutics plc
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 24 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2024, 17:16:03 UTC
- Prior SEC filing
- 16 Jun 2023
- Next SEC filing
- 17 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Frank Thomas, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Curnutte John T. filed Form 4 for Orchard Therapeutics plc on 24 Jan 2024.
Change
- Previous filing in this sequence was filed on 16 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORTX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -46,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 24 Jan 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 46,000
- Exercise price
- $0.4750
- Footnotes
- F1, F2, F3
ORTX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -105,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 24 Jan 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 105,000
- Exercise price
- $0.4950
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Curnutte John T. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.
Footnote F2
Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.
Footnote F3
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.